Cargando…

Efficacy and Safety of Shexiang Baoxin Pill for Coronary Heart Disease after Percutaneous Coronary Intervention: A Systematic Review and Meta-analysis

OBJECTIVE: Shexiang Baoxin Pill (SBP) is a licensed Chinese herbal pharmaceutical that has been widely accustomed to treat coronary heart disease (CHD) after percutaneous coronary intervention (PCI). This study points to systematically assess the efficacy and security of the combination of SBP with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wei, Jingjing, Liu, Shanshan, Wang, Xinlu, Li, Bin, Qiao, Lijie, Wang, Yongxia, Zhu, Mingjun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2021
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8684521/ https://www.ncbi.nlm.nih.gov/pubmed/34931125 http://dx.doi.org/10.1155/2021/2672516

Ejemplares similares

Efficacy and safety of Shexiang Baoxin Pill for stable coronary artery disease: A systematic review and meta-analysis of 42 randomized controlled trials
por: Wei, Jingjing, et al.
Publicado: (2022)

Meta-analysis and trial sequential analysis of shexiang baoxin pill for coronary slow flow
por: Guo, Hongxin, et al.
Publicado: (2022)

Shexiang Baoxin Pills for Coronary Heart Disease in Animal Models: Preclinical Evidence and Promoting Angiogenesis Mechanism
por: Zhang, Ke-Jian, et al.
Publicado: (2017)

Effects of Shexiang Baoxin Pill for Coronary Microvascular Function: A Systematic Review and Meta-Analysis
por: Wang, Mengxi, et al.
Publicado: (2021)

Shexiang Baoxin Pills as an Adjuvant Treatment for Chronic Heart Failure: A System Review and Meta-Analysis
por: Dong, Taiwei, et al.
Publicado: (2018)

Metabolomic Strategy for Studying the Intervention and the Synergistic Effects of the Shexiang Baoxin Pill for Treating Myocardial Infarction in Rats
por: Xiang, Li, et al.
Publicado: (2013)

Protective Effect of Shexiang Baoxin Pill on Myocardial Ischemia/Reperfusion Injury in Patients With STEMI
por: Qin, Haixia, et al.
Publicado: (2021)

Block Matching Pyramid Algorithm-Based Analysis on Efficacy of Shexiang Baoxin Pills Guided by Echocardiogram (ECG) on Patients with Angina Pectoris in Coronary Heart Disease
por: Gao, Junqing, et al.
Publicado: (2021)

A network-based method for mechanistic investigation of Shexiang Baoxin Pill’s treatment of cardiovascular diseases
por: Fang, Hai-Yang, et al.
Publicado: (2017)

Shexiang Baoxin Pill for Acute Myocardial Infarction: Clinical Evidence and Molecular Mechanism of Antioxidative Stress
por: Guo, Jianbo, et al.
Publicado: (2021)

Shexiang Baoxin Pill Corrects Metabolic Disorders in a Rat Model of Metabolic Syndrome by Targeting Mitochondria
por: Wei, Dan, et al.
Publicado: (2018)

Co-administration of Shexiang Baoxin Pill and Chemotherapy Drugs Potentiated Cancer Therapy by Vascular-Promoting Strategy
por: Yang, Liu-qing, et al.
Publicado: (2019)

Efficacy and safety of the Shexiang Baoxin Pill for the treatment of coronary artery disease not amenable to revascularisation: study protocol for a randomised, placebo-controlled, double-blinded trial
por: Tian, Pan-pan, et al.
Publicado: (2018)

Efficacy of Shexiang Baoxin Pills for the treatment of unstable angina pectoris: Protocol of systemic review and meta-analysis
por: Chen, Huadong, et al.
Publicado: (2019)

Effectiveness and safety of Shexiang Baoxin Pill (MUSKARDIA) in patients with stable coronary artery disease and concomitant diabetes mellitus: a subgroup analysis of a randomized clinical trial
por: Zhou, Jingmin, et al.
Publicado: (2023)

Efficacy and safety of Shexiang Baoxin pill (MUSKARDIA) in patients with stable coronary artery disease: a multicenter, double-blind, placebo-controlled phase IV randomized clinical trial
por: Ge, Jun-Bo, et al.
Publicado: (2021)

Shexiang Baoxin Pills Inhibited Proliferation and Migration of Human Coronary Artery Smooth Muscle Cells via PI3K/AKT/mTOR Pathway
por: Hua, Lei, et al.
Publicado: (2021)

Shexiang Baoxin Pill, Derived From the Traditional Chinese Medicine, Provides Protective Roles Against Cardiovascular Diseases
por: Lu, Li, et al.
Publicado: (2018)

Antidepressant and anxiolytic effects of the proprietary Chinese medicine Shexiang Baoxin pill in mice with chronic unpredictable mild stress
por: Zhou, Xi-Dan, et al.
Publicado: (2018)

Therapeutic efficacy and safety of Shexiang Baoxin Pill combined with trimetazidine in elderly patients with heart failure secondary to ischaemic cardiomyopathy: A systematic review and meta-analysis
por: Wen, Jianxia, et al.
Publicado: (2018)

Shexiang Baoxin Pill Alleviates the Atherosclerotic Lesions in Mice via Improving Inflammation Response and Inhibiting Lipid Accumulation in the Arterial Wall
por: Lu, Li, et al.
Publicado: (2019)

Shexiang Baoxin Pill, a Traditional Chinese Herbal Formula, Rescues the Cognitive Impairments in APP/PS1 Transgenic Mice
por: Hu, Wei-Hui, et al.
Publicado: (2020)

Shexiang Baoxin Pill (MUSKARDIA) reduces major adverse cardiovascular events in women with stable coronary artery disease: A subgroup analysis of a phase IV randomized clinical trial
por: Shi, Haiming, et al.
Publicado: (2022)

Single-nucleus ribonucleic acid-sequencing and spatial transcriptomics reveal the cardioprotection of Shexiang Baoxin Pill (SBP) in mice with myocardial ischemia-reperfusion injury
por: Lin, Wenyong, et al.
Publicado: (2023)

Therapeutic Efficacy of Shexiang Baoxin Pill Combined with Exercise in Patients with Heart Failure with Preserved Ejection Fraction: A Single-Center, Double-Blind, Randomized Controlled Trial
por: Liu, Si-pei, et al.
Publicado: (2022)

Efficacy and safety of Shexiang Baoxin Pill combined with Western medicine in the treatment of acute myocardial infarction: A single-center, double-blind, randomized controlled trial
por: Yang, Yan, et al.
Publicado: (2021)

Shexiang Baoxin Pills Could Alleviate Isoproterenol-Induced Heart Failure Probably through its Inhibition of CaV1.2 Calcium Channel Currents
por: Wu, Jianwei, et al.
Publicado: (2022)

Efficacy of Shexiang Tongxin Dropping Pills in a Swine Model of Coronary Slow Flow
por: Bai, Yupeng, et al.
Publicado: (2022)

The Efficacy and Safety of Compound Danshen Dripping Pill Combined with Percutaneous Coronary Intervention for Coronary Heart Disease
por: Li, Cailan, et al.
Publicado: (2020)

Shexiang Baoxin Pill, a Formulated Chinese Herbal Mixture, Induces Neuronal Differentiation of PC12 Cells: A Signaling Triggered by Activation of Protein Kinase A
por: Xu, Miranda Li, et al.
Publicado: (2019)

Shexiang Baoxin Pill, a Proprietary Multi-Constituent Chinese Medicine, Prevents Locomotor and Cognitive Impairment Caused by Brain Ischemia and Reperfusion Injury in Rats: A Potential Therapy for Neuropsychiatric Sequelae of Stroke
por: Qin, Zong-Shi, et al.
Publicado: (2021)

Effect of Shexiang Tongxin dropping pill on stable coronary artery disease patients with normal fractional flow reserve and coronary microvascular disease: A study protocol
por: Lu, Yanli, et al.
Publicado: (2020)

Shexiang Tongxin dropping pill protects against isoproterenol-induced myocardial ischemia in vivo and in vitro
por: Qi, Jianyong, et al.
Publicado: (2017)

Protective effects of Shexiang Tongxin Dropping Pill on pituitrin-induced acute myocardial ischemia in rats
por: Lin, Shan, et al.
Publicado: (2017)

Shexiang Tongxin Dropping Pills Promote Macrophage Polarization-Induced Angiogenesis Against Coronary Microvascular Dysfunction via PI3K/Akt/mTORC1 Pathway
por: Lu, Xiangyu, et al.
Publicado: (2022)

LC-MS-based metabolomics reveals the mechanism of anti-gouty arthritis effect of Wuwei Shexiang pill
por: Lang, Jirui, et al.
Publicado: (2023)

Efficacy and Safety of Qili Qiangxin Capsule on Dilated Cardiomyopathy: A Systematic Review and Meta-Analysis of 35 Randomized Controlled Trials
por: Wei, Jingjing, et al.
Publicado: (2022)

Efficacy and Mechanism of Buyang Huanwu Decoction in Patients With Ischemic Heart Failure: A Randomized, Double-Blind, Placebo-Controlled Trial Combined With Proteomic Analysis
por: Zhu, Mingjun, et al.
Publicado: (2022)

Tongmai Yangxin intervening in myocardial remodeling after PCI for coronary heart disease: study protocol for a double-blind, randomized controlled trial
por: Wang, Yongxia, et al.
Publicado: (2020)

Compound Danshen Dripping Pill Pretreatment to Prevent Contrast-Induced Nephropathy in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
por: Yang, Rong, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_938jut1au238jo78je3tbhjf6o